TABLE 1.
Univariate analysis of demographic and treatment-related factors for the 329 consecutive patients who were evaluated for pancreatic adenocarcinoma between 1990 and 2002 and underwent resection
| Clinical factor | Total | Survival <5 years |
Survival ≥5 years |
P value |
|---|---|---|---|---|
| Patients (n) | 329 | 241 | 88 | |
| Demographics | ||||
| Sex, n (%) | .34 | |||
| Male | 190 (58) | 143 (59) | 47 (53) | |
| Female | 139 (42) | 98 (41) | 41 (47) | |
| Age (years) | .70 | |||
| Median (mean) | 64 (63) | 64 (63) | 63 (62) | |
| Range | 30–85 | 39–82 | 30–85 | |
| Surgery | ||||
| Type of operation, n (%) | .26 | |||
| Pancreaticoduodenectomy | 302 (92) | 219 (91) | 83 (94) | |
| Distal pancreatectomy | 20 (6) | 15 (6) | 5 (6) | |
| Total pancreatectomy | 7 (2) | 7 (3) | 0 (0) | |
| Reoperative, n (%) | 48 (15) | 43 (18) | 5 (6) | .006 |
| Vascular resection, n (%) | 108 (33) | 83 (34) | 25 (28) | .30 |
| Superior mesenteric or portal vein | 101 (31) | 76 (32) | 25 (28) | |
| CHA | 9 (3) | 7 (3) | 2 (2) | |
| Inferior vena cava | 4 (1) | 4 (2) | 0 (0) | |
| Operative blood loss (ml) | .08 | |||
| Median (mean) | 950 (1289) | 1000 (1374) | 900 (1057) | |
| Range | 100–18,000 | 100–18,000 | 125–3600 | |
| Length of stay (days) | .14 | |||
| Median (mean) | 12 (15) | 13 (15) | 11 (13) | |
| Range | 5–108 | 5–108 | 6–41 | |
| Additional therapy | ||||
| Neoadjuvant treatment, n (%) | 253 (77) | 188 (78) | 65 (74) | .43 |
| Chemotherapy | 36 (11) | 27 (11) | 9 (10) | |
| Chemoradiation | 248 (76) | 185 (77) | 63 (72) | |
| Adjuvant treatment, n (%) | 59 (18) | 42 (18) | 17 (20) | .68 |
| Chemotherapy | 19 (6) | 15 (6) | 4 (5) | |
| Chemoradiation | 49 (15) | 34 (14) | 15 (17) | |
| Surgery alone, n (%) | 25 (8) | 18 (7) | 7 (8) | .95 |
| Tumor histopathology | ||||
| Tumor size (cm) | .09 | |||
| Median (mean) | 3.0 (3.0) | 3.0 (3.1) | 3.0 (2.8) | |
| Range | .2–13 | .2–13 | .3–8.0 | |
| Margin status, n (%) | .04 | |||
| R0 | 277 (84) | 197 (82) | 80 (91) | |
| R1 | 52 (16) | 44 (18) | 8 (9) | |
| Lymph node status, n (%) | .01 | |||
| N0 | 172 (52) | 116 (48) | 56 (64) | |
| N1 | 157 (48) | 125 (52) | 32 (36) | |
| Lymph node ratio, n (%)a | .05 | |||
| 0 | 171 (52) | 115 (48) | 56 (64) | |
| 0–.2 | 93 (28) | 72 (30) | 21 (24) | |
| .2–.4 | 44 (13) | 35 (15) | 9 (10) | |
| >.4 | 20 (6) | 18 (7) | 2 (2)b |
P comparison between survival cohorts
a
Ratio of the number of positive lymph nodes to the number examined
b
Adenocarcinoma identified in 6 of 12 nodes in one patient and 1 of 2 in the other
CHA common hepatic artery